S
S. Pilotti
Researcher at University of Trieste
Publications - 111
Citations - 5998
S. Pilotti is an academic researcher from University of Trieste. The author has contributed to research in topics: Carcinoma & Trabectedin. The author has an hindex of 39, co-authored 111 publications receiving 5569 citations. Previous affiliations of S. Pilotti include University of Nice Sophia Antipolis & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.
TL;DR: Results indicate that mutations of the p53 gene are associated with the most aggressive histologic types of thyroid tumors, such as the undifferentiated carcinoma and, to a certain extent, the poorly differentiated carcinoma, and that the alterations of this gene represent a late genetic event in human thyroid carcinogenesis.
Journal Article
A Comparative Study of p53 Gene Mutations, Protein Accumulation, and Response to Cisplatin-based Chemotherapy in Advanced Ovarian Carcinoma
Sabina C. Righetti,G. Della Torre,S. Pilotti,Sylvie Ménard,F. Ottone,Maria I. Colnaghi,M.A. Pierotti,Cinzia Lavarino,M Cornarotti,S Oriana,S. Bohm,G L Bresciani,G. Spatti,Franco Zunino +13 more
TL;DR: A significant correlation has been found between p53 accumulation, type of mutation, and pathological response to cisplatin-based therapy in ovarian cancer patients, consistent with a role of p53 as a determinant of chemosensitivity of ovarian carcinoma.
Journal ArticleDOI
Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer.
Nadia Zaffaroni,Marzia Pennati,Gennaro Colella,Paola Perego,Rosanna Supino,Laura Gatti,S. Pilotti,F. Zunino,Maria Grazia Daidone +8 more
TL;DR: Cellular studies and clinical data suggest a direct link between survivin expression and tumour cell susceptibility to taxol, and indirectly supported by similar observations obtained with clinical tumours.
Journal Article
Deletions of 17p and p53 mutations in preneoplastic lesions of the lung.
Gabriella Sozzi,Monica Miozzo,R. Donghi,S. Pilotti,C.T. Cariani,Ugo Pastorino,G. Della Porta,M. A. Pierotti +7 more
TL;DR: Cytogenetic and p53 mutation analysis in two cases of severe dysplasia of the bronchial epithelium in lung cancer patients and p 53 immunostaining in a third one indicates that changes may take place early in the process of lung carcinogenesis.
Journal ArticleDOI
Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Giovanni Germano,Roberta Frapolli,Matteo Simone,Michele Tavecchio,Eugenio Erba,Samantha Pesce,Fabio Pasqualini,Federica Grosso,Roberta Sanfilippo,Paolo G. Casali,Alessandro Gronchi,Emanuela Virdis,Eva Tarantino,S. Pilotti,Angela Greco,Manuela Nebuloni,Carlos M. Galmarini,Juan Carlos Tercero,Alberto Mantovani,Maurizio D'Incalci,Paola Allavena +20 more
TL;DR: In conclusion, trabectedin has dual effects in liposarcoma: in addition to direct growth inhibition, it affects the tumor microenvironment by reducing the production of key inflammatory mediators.